Apelin is the endogenous peptide APJ receptor, while APJ is a member of the G protein-coupled receptors family. Recent evidence strongly suggests that Apelin/APJ system influences apoptosis in various diseases through different signal pathways. In this review, we discuss the possible mechanisms by which the Apelin/APJ system inhibits apoptosis, including the phosphatidylinositol-3-kinase (PI3K)/Akt, ERK1/2, caspase signaling, and autophagy pathway. We also summarize the role of Apelin/APJ system in apoptosis in myocardial ischemia-reperfusion (I/R) injury, pulmonary artery hypertension, retinal neovascular disease, acute renal injury, skeletal homeostasis, and gastrointestinal diseases. Apelin/APJ system decreases myocardial infarction size and alleviates myocardial I/R injury by inhibiting cardiomyocytes apoptosis. However, Apelin/APJ system improves pulmonary artery hypertension via increasing apoptosis. Apelin/APJ system exerts neuroprotective effect by blocking apoptosis and participates in the recovery of retinal neovascular disease by suppressing apoptosis. Apelin/APJ system also shows anti-apoptotic effect against acute renal injury and plays a role in regulating skeletal homeostasis. In gastrointestinal disease, Apelin/APJ system plays a potential physiological role in gastrointestinal cytoprotection by regulating apoptosis. We hope that a better understanding of the Apelin/APJ system will help to discover new disease pathogenesis and find possible therapeutic targets of the Apelin/APJ system essential for various diseases.
Introduction
Apelin is a novel peptide which was first found in bovine stomach extracts. Apelin acts as the endogenous ligand for the orphan G protein-coupled receptor APJ [1] , and shares similarities with the angiotensin II-angiotensin II type 1 receptor (AT1) pathway [2] . Multiple Apelin peptides have been detected or sythesized including Apelins-12, -13, -15, -16, -17, -19, -28, -31, and Apelin-36 [1, [3] [4] [5] . Among these Apelin isoforms, there are at least four bioactive forms, including Apelins-12, -13, -17, and Apelin-36 [6, 7] , with Apelin-13 and Apelin-36 being the main forms. Apelin and APJ exist in a variety of tissues such as the heart, lung, brain, kidney, liver, blood vessels, gastrointestinal tract, and adipose tissue [8] , suggesting that the Apelin/APJ system may be involved in a wide range of physiological and pathological processes. However, the main distribution of Apelin-13 and Apelin-36 may be different. Apelin-36 is the major component in the lung, testis, and uterus, while Apelin-13 mainly exists in the mammary gland. Apelin/APJ system is also involved in the regulatory process of the central and peripheral cardiovascular system [9] [10] [11] , which functions as a crucial mediator of cardiovascular homeostasis and diseases [12] [13] [14] . Numerous researches showed that Apelin/APJ system plays a key role in inhibiting the development of hypertension, pulmonary hypertension, myocardial ischemia-reperfusion (I/R) injury, etc. In addition, the Apelin/APJ system also participates in some biological processes, such as apoptosis. In this review, we focus on the relationship between Apelin/APJ system and apoptosis, aiming to provide a new mechanism for the treatment of diseases.
Apelin/APJ System Plays an Important Role in Apoptosis
Apoptosis is a process of programmed cell death that occurs in multicellular organisms. It is well established that Apelin/APJ system may regulate apoptosis in various cell types, then mediate the occurrence and development of related-diseases. Several in vitro studies have suggested that Apelin/APJ suppresses apoptosis in different types of cultured cells, such as endothelial cells [15] , cardiomyocytes [16] , LoVo cells [17] , retinal Muller cells [18] , and smooth muscle cell [19] . The increase in Apelin-13 inhibits apoptosis and mitochondrial damage in cardiomyoblast cell line H9C2, and protects against I/R injury and obesity [20] . Vascular smooth muscle cells (VSMCs) play a key role in regulating vascular remodeling in cardiovascular diseases. Moreover, Apelin/APJ system inhibits VSMC apoptosis induced by serum deprivation [21] . However, Apelin/APJ system was shown to induce apoptosis of pulmonary arterial SMCs (PASMCs), and the sharp decrease of Apelin was proposed as a potential biomarker for pulmonary arterial hypertension (PAH) [22] . The alterations of these cell activities induced by apelin are associated with the onset and development of different diseases, such as myocardial I/R injury, PAH, neuroprotective effect, retinal neovascular disease, acute renal injury, skeletal homeostasis, and gastrointestinal disease. Apelin/APJ system may participate in the development of various diseases by regulating apoptosis. Apelin/APJ system is closely related to the cardiovascular disorders via its antiapoptotic activity. However, Apelin/APJ system reduces I/R injury and inhibits the formation of pulmonary hypertension by its proapoptotic property. Meanwhile, Apelin/APJ system exerts strong neuroprotective effects through disturbing the balance between antiapoptotic and pro-apoptotic functions. In the gastrointestinal system, Apelin/APJ system also has a positive protective effect via the regulation of apoptosis. Of note, apoptosis plays an important role in these diseases. Although few articles have discussed the relationship between Apelin/APJ system and cancer, our lab has discovered that Apelin-13 promotes the migration of lung adenocarcinoma cells [23] . In cancer cells, most anticancer therapies exert their function by triggering apoptosis in cancer cells. We propose that apoptosis may play a vital role in anticancer therapy, and Apelin/APJ system may be applied to the treatment of cancers by regulating apoptosis. Apelin/APJ system may inhibit or promote apoptosis by acting on different apoptotic-related proteins under diverse conditions and circumstances of various diseases ( Table 1) .
Potential Mechanisms of Apelin/APJ System in Apoptosis
Apelin/APJ system inhibits apoptosis through PI3K/Akt pathway Apelin/APJ system inhibits apoptosis via the modulation of apoptotic proteins by PI3K/Akt pathway. Apoptosis is the most common cause of ischemic heart dysfunction, and Apelin/APJ system protects ischemic cardiomyocytes from apoptosis. However, the mechanism has not been discussed further. Pretreatment of cardiomyocytes with Apelin-13 would effectively inhibit glucose deprivation (GD)-induced apoptosis and may significantly increase Akt and mTOR phosphorylation with up-regulation of Bcl-2 protein and downregulation of Bax and cleaved caspase-3 [27] . Apelin/APJ system also increases the expression of Bcl-2, and decreases the expression of Bax protein. After Apelin stimulation, ERK and Akt activation would increase. Suppression of APJ with siRNA blocks the Apelininduced activation of ERK and Akt [21] . Furthermore Apelin-13 could exert anti-apoptotic effects in MSCs and would be an effective approach in cell therapy of diabetes in cardiovascular system [28] . Furthermore, in the central nervous system, in the MCAO model and in the neonatal hypoxic/ischemic (H/I) injury model, Apelin-36 increases the phosphorylated Akt level after H/I injury, and inhibitor of PI3K decreases the level of phosphorylated Akt and attenuates the protective effects of Apelin-36 on apoptosis [30] . It has been proved that Apelin may protect the heart from I/R injury through the activation of PI3K/Akt and ERK signaling pathways. The neuroprotective effect of Apelin-13 was also found in brain I/R injury [37] . In mouse or human osteoblasts [33, 34] , bone marrow-derived mesenchymal stem cells [38] , and LoVo cells, Apelin may also regulate apoptosis through PI3K/Akt pathways. Pro-apoptotic [85] PI3K is necessary for the translocation of Akt to the plasma membrane as a second messenger [39] . PI3K phosphorylates a variety of substrates and activates Akt, which plays a crucial role in fundamental cellular functions such as cell proliferation and survival. Activating the PI3K/Akt signaling pathway by many types of external factors such as cellular stimuli or toxic insults also regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival [40, 41] . PI3K/Akt is an important regulator of anti-apoptotic activity, and it activates or inhibits its downstream target proteins by phosphorylation, such as caspase-9, BAD, mTOR, NF-κB, Forkhead, Par-4, and P21, and mediates various growth factors to regulate several cellular functions including nutrient metabolism, cell growth, apoptosis, and survival [42] . However, there are three possible mechanisms of anti-apoptotic function: (i) Direct regulation through cascade activation. The Bcl-2 family plays a role in apoptosis regulation, consisting of proapoptotic members and anti-apoptotic members. The heterodimerizing of nonphosphory BAD with Bcl-XL or Bcl-2, neutralizes their protective effect and promotes cell death. The death-promoting effect of BAD may be inhibited when phosphorylated BAD is sequestered in the cytosol and bound to the 14-3-3 protein [43, 44] . Akt is a key BAD kinase which activates phosphorylation of Ser136 in BAD sites. When the phosphorylated BAD binds to the 14-3-3 protein, they prevent BAD from forming dimmers with the Bcl-2 or Bcl-XL, therefore effectively blocks apoptosis induced by BAD, and inhibits pro-apoptotic activities. The phosphorylation induced by Akt of another pro-apoptotic protein Bax also shows its proapoptotic function negatively [45] . After treatment with specific PI3K inhibitor wortmannin and LY294002, the Akt-induced phosphorylation of BAD and Bax is inhibited. (ii) Directly or indirectly affecting the transcription factor family (NF-κB, p53, Forkhead, etc.). Forkhead transcription factors of the FoxO family are significant downstream targets of protein kinase B (PKB)/Akt, and these kinases play key roles in cell proliferation and survival. Forkhead or FoxO family members have four subtypes (FKHR/ FoxO1, FoxO2, FKHRL1/FoxO3, and AFX/FoxO4), and all are directly phosphorylated by Akt. Phosphorylation of Forkhead may negatively regulate apoptosis [46] . P53, the tumor suppressor protein, damages cell DNA and induces apoptosis. MDM2, which could bind to p53 protein, inactivates the function of p53 in transcriptional regulation and regulates its pro-apoptotic function negatively. PI3K/Akt signaling promotes the phosphorylation of the MDM2 and induces its binding with p53, thus leading to the p53 inactivation or degradation, which reverses apoptosis mediated by p53 [47, 48] . (iii) Inhibiting the release of mitochondrial apoptosis factors. The activation of Akt inhibits the release of mitochondrial cytochrome c to protect against apoptosis [49] . Apelin/APJ system may regulate apoptosis by PI3K/Akt. These pathways are the major signals reported to be correlated with apoptosis. Therefore, we guess that Apelin may inhibit apoptosis through these common pathways (Fig. 1) .
Apelin/APJ system inhibits apoptosis by ERK1/2 signaling pathway ERK is an important component of the Ras-Raf-MEK-ERK signaling pathway cascades, which mediates intracellular stimuli transduction and gene expression. ERK1 (44 kDa) and ERK2 (42 kDa) are members of the mitogen-activated protein kinase (MAPK) family, and are involved in the regulation of a wide variety of cell activities, including cell migration, proliferation, and differentiation [50] . Phosphorylated ERK1/2 (pERK) mediate the expression of genes, leading to cell proliferation, cell differentiation [51] , and the inhibition of apoptosis in response to a wide range of stimuli, such as tumor necrosis factor (TNF), Fas ligand, TNF-related apoptosisinducing ligand (TRAIL) [52] , osmotic stress [53] [54] [55] , radiation [56, 57] , nitric oxide [58] , hypoxia [59] , growth factor withdrawal [60] , hydrogen peroxide [61] , matrix detachment [62] , and chemotherapeutic agents.
In response to most of these stimuli, ERK1/2 exerts its antiapoptotic effect by undergoing either transient or prolonged activation, but the mechanism is complicated. ERK1/2 inhibit the release of cytochrome c from mitochondria and the downstream molecules, thereby reducing apoptosis [60, 63] . ERK1/2, as the upstream regulating kinases, activate the NF-κB, regulate the expression of antiapoptotic genes Bcl-2 and Bcl-XL, reduce the phosphorylation of pro-apoptotic protein Bad, and promote the degradation of Bad, Bax, and Bim, eventually resulting in strong anti-apoptotic effects. However, inhibition the ERK1/2 activation enhances the expression of caspases-3, 8, 9, and promotes apoptosis.
Though the mechanism of ERK1/2 in mediating apoptosis is complicated, there are few reports indicating that Apelin/APJ system attenuates apoptosis by MAPK/ERK1/2 and PI3K/Akt signaling pathways (Fig. 2) .
Apelin/APJ system inhibits apoptosis by caspase
Caspases, which are highly conserved cysteine protease family members in multicellular organisms, function as the central regulators of cell death. Actually, some caspases are significantly important for apoptosis, and the majority of caspases not only participate in executing the function of apoptosis, but also are involved in cell proliferation, survival, differentiation, or inflammation [64] [65] [66] . Based on their pro-apoptotic functions, caspases are divided into two categories: the initiator caspases, which include caspases-2, -8, -9, and -10, and the effector caspases, which include caspases-3, -6, and -7. However, much evidence has suggested that Apelin/APJ system plays an essential role in apoptosis by activating or inhibiting these caspases.
Apelin and its receptor APJ are abundantly expressed in the cardiovascular and nervous systems. Apelin-13 protects cardiomyocytes from ischemic injury as well as apoptosis. In addition, Apelin-13 reduces brain edema and inhibits apoptosis by decreasing caspase-3 activation [67] . Apoptosis is correlated with the fluctuation of caspase to a certain extent. While in PASMCs and enterocyte model Caco-2 cells, Apelin also stimulates apoptosis [22] . However, the mechanisms are still unclear. We speculate that different subtypes, diverse pathways, various environments, and treatment factors may participate in this process. Thus, further research is required to clarify this mechanism.
Caspase-3 is activated via an extrinsic or intrinsic signaling pathway [68] . In the extrinsic pathway, caspase-8 is activated by Fas (fibroblast-associated antigen, also called Apo-1 or CD95) and tumor necrosis factor receptor stimulation, and is subsequently hydrolyzed. In the intrinsic pathway, caspase-8 is activated by a variety of extra-and intracellular stresses, such as irradiation, oxidative stress, and treatment with cytotoxic drugs [69, 70] . Caspase-8 also cleaves the BH3-only protein Bid. The resulting truncated Bid (tBid) is then transferred into the mitochondria and causes the release of cytochrome c from the mitochondria. The above studies suggest that Apelin/APJ system suppresses apoptosis via regulating various caspases.
Apelin/APJ system suppresses apoptosis via autophagy
Apoptosis, autophagy, and ferroptosis [71] are evolutionarilyconserved processes that regulate cell death. Both apoptosis and Apelin inhibits apoptosis via ERK1/2 signaling ERK1/2 can be activated by numerous external stimuli, such as tumor necrosis factor (TNF), Fas ligand, TNF-related apoptosis-inducing ligand (TRAIL), radiation, nitric oxide (NO), hypoxia, and H 2 O 2 , which leads to anti-apoptotic effects. Apelin may regulate ERK1/2, which inhibits cytochrome c release from the mitochondria, leading to the suppression of apoptosis. ERK1/2 simulates NF-κB signaling, increases the expression of Bcl-2, and decreases the expression of Bax, which leads to the inhibition of apoptosis. Apelin/APJ may be used as an external stimulus to inhibit apoptosis by stimulating ERK1/2. autophagy are of great importance for development, normal physiology, and various diseases [72] . Autophagy is vital in cell death decisions and it protects cells by preventing them from undergoing various apoptotic stimuli [73] . Increasing autophagy allows cell survival by inhibiting apoptosis [74] . Despite the obvious differences between these two processes, their regulations are intimately connected and the same regulator may sometimes control both apoptosis and autophagy.
Apelin/APJ system inhibits apoptosis by promoting autophagy. Previous studies have shown that Apelin/APJ system inhibits mesenchymal stem cells apoptosis by promoting protective autophagy via AMPK during hypoxia. However, Apelin/APJ system suppresses autophagic cell death during reoxygenation by activating Akt and inhibiting Beclin1 [75] . Additionally, Apelin/APJ system reduces apoptosis of neural cells by suppressing autophagy in brain I/R injury [76] . Thus, autophagy may produce contradictory effect. Autophagy inhibits apoptosis under hypoxia, while autophagy may induce apoptosis under reoxygenation or reperfusion. Furthermore, Apelin/APJ system inhibits GD-induced cardiomyocyte autophagy by PI3K/Akt signaling [77] , while Apelin/APJ system also decreases GD-induced cardiomyocyte apoptosis via PI3K/Akt signaling [27] . Apelin/APJ system may inhibit GD-induced cardiomyocyte apoptosis by inhibiting autophagy via PI3K/Akt signaling. Therefore, apoptosis and autophagy are closely related in Apelin/APJ system to regulate cell death.
Apelin/APJ System May Be a Potential Therapeutic Target in Apoptosis-related Diseases
Apelin/APJ system alleviates myocardial I/R injury by inhibiting apoptosis Myocardial I/R injury is a common pathophysiological process in patients with heart diseases and therapies. Previous studies have shown that excessive oxygen free radicals attack the blood supply organization, which leads to cardiomyocyte apoptosis and myocardial infarction (MI). Apelin/APJ system dramatically promotes the expression of post-MI indicator protein in infarcted hearts, which increases angiogenesis and improves cardiac repair of post-MI by suppressing apoptosis [25] . Similar results were reported by Li et al. [26] that administration of Apelin significantly increases bone marrow cell (BMC) recruitment and promotes cardiac repair after MI accompanied by suppressing stress-induced apoptosis. Apelin/APJ system inhibits apoptosis by different pathways in various I/R models. In high-fat diet-induced obesity rat, Apelin/APJ system protects against I/R-mediated apoptosis through the FoxO1 pathway [20] . Apelin/ APJ system protects ischemic cardiomyocytes from apoptosis induced by glucose deprivation and exerts cardioprotective effects during myocardial injury [27] . In an in vivo rat I/R model, Apelin/APJ system was found to significantly attenuate time-related ER stress-induced apoptosis and protect the heart from I/R injury [16, 24] . Similar results were also reported by Zeng et al. [78] . They demonstrated that Apelin/APJ system inhibits apoptosis and improves myocardial I/R injury by enhancing superoxide dismutase activity and phosphorylation of ERK1/2 and Akt [78] . Therefore, Apelin/APJ system may protect against myocardial I/R injury by inhibiting apoptosis, and it may be a potential target for myocardial I/R injury.
Apelin/APJ system relieves pulmonary artery hypertension process by promoting apoptosis Patients with PAH have less Apelin and the expression of Apelin is decreased in pulmonary endothelial cells [19] . Apelin has therefore been proposed to be a potential biomarker for PAH. Apelindeficient cells are more susceptible to apoptosis. In addition, Apelin deficiency promotes proliferation of pulmonary arterial smooth muscle cells. On the contrary, Apelin administration suppresses proliferation and induces apoptosis of PASMCs, and reverses PAH in mice [22] . Apelin in other cells, such as H9C2, PC12 cells, LoVo cells, show anti-apoptotic effects, but in PASMCs, it plays a completely opposite role. Pulmonary hypertension is associated with abnormal cell proliferation. We speculate that cell proliferation and cell death are in a dynamic equilibrium state. Apelin/APJ system inhibits cell proliferation by blocking cell cycle, and this is likely to increase apoptosis. In our point of view, this is why Apelin/APJ system expresses pro-apoptotic effects.
Apelin/APJ system shows neuroprotective effect by blocking apoptosis Some diseases such as Krabbe's disease, epilepsy, cerebrovascular disease are the most common neurological diseases. Cerebral ischemia may cause the corresponding neurological symptoms of the disease. Previous studies have shown that Apelin-13 is a potential protective agent for cardiac I/R injury. The effect of Apelin/APJ system on the central nervous system gradually becomes clear. Recently, the potential protective activity of Apelin-13 in PC12 cells has been explored. It was found that Apelin-13 inhibits the apoptosis of PC12 cells induced by corticosterone, suggesting its typical neuroprotective function [29] . In addition to activating the PI3K and ERKs pathways [37] , the effect of Apelin-13 on apoptosis may be associated with AMPK signals [79] . Similar results were also reported by Yan et al. [80] that Apelin-13 has neuroprotective function. Zeng et al. [81] also explored the influence of Apelin/APJ system on apoptosis in mouse primary cultures of cortical neurons. All these results demonstrate that Apelin-13 may inhibit apoptosis and excitotoxic death through cellular and molecular mechanisms as an endogenous neuroprotective adipocytokine. Thus, Apelin is a promising neuroprotective agent for cerebral ischemic brain damage. Furthermore, Khaksari et al. [67] reported that Apelin-13 provides protection in transient focal cerebral ischemia by blocking apoptosis. Besides Apelin-13, Apelin-36, a long form of Apelin, significantly enhances anti-apoptotic activity in the middle cerebral artery occlusion (MCAO) model and the neonatal hypoxic/ischemic (H/I) injury model, suggesting that Apelin-36 may be a promising therapeutic agent for the treatment of ischemic brain injury [30] . Therefore, Apelin-13 and apein-36 can inhibit apoptosis caused by I/R injury, and have strong neuroprotective effect.
Apelin/APJ system blocks the process of retinal neovascular disease by inhibiting apoptosis Apelin/APJ system is involved in the regulation of retinal vasculogenesis and angiogenesis by inhibiting Muller cells and pericytes apoptosis. Muller cells support the blood-retinal barrier integrity, and its dysfunction in pathological conditions may lead to the formation retinal edema. Lu et al. [18] reported that Apelin-13 inhibits apoptosis of retinal Muller cells and regulates its survival under hypoxia. Therefore, pericytes in the pathogenesis of retinal neovascular diseases has attracted much attention, such as diabetic retinopathy and premature retinopathy. Wang et al. [82] revealed that Apelin prevents apoptosis induced by hypoxia, indicating that Apelin may provide potential protection for blood-retinal barrier to ischemia. They also demonstrated that Apelin/APJ system effectively suppresses hypoxia-induced apoptosis of pericytes and protects against pericyte injury [31] . Therefore, Apelin/APJ system may be involved in the treatment of retinal diseases by inhibiting the apoptosis of retinal cells.
Apelin/APJ system protects against acute renal injury via reducing apoptosis Renal I/R injury is a major cause of acute kidney injury (AKI) after major surgery or renal transplantation in both allograft and native kidneys [83] . Recently, some researchers demonstrated that administration of Apelin-13 reduces kidney and glomerular hypertrophy [32] . To test whether Apelin-13 can prevent against renal I/R-induced injury, Chen et al. [35] investigated the role of Apelin in acute renal injury, and found that Apelin-13 treatment significantly reduced the injury-induced apoptosis of renal cells. Moreover, under the in vitro hypoxia/reperfusion (H/R) conditions, over-expression of Apelin-13 also suppressed H/R-induced apoptosis [35] . Therefore, Apelin-13 may also be a promising therapeutic agent for AKI.
Apelin/APJ system increases skeletal homeostasis through the decline of osteoblasts apoptosis Adipose tissue plays an important role in bone metabolism, and can identify adipocytokines, affecting bone mass. Apelin, a special adipokine, has been reported to stimulate MC3T3-E1 cell proliferation and inhibit mouse osteoblast apoptosis induced by serum deprivation [33] . Similar results were also shown in human osteoblasts [34] . Moreover, suppression of APJ with small-interfering RNA (siRNA) blocks the anti-apoptotic activity of Apelin. Wattanachanya et al. [84] observed the direct effects of Apelin on bone cells in vitro by comparing the skeletal phenotypes of the Apelin-knockout (APKO) mice with that of the wild-type mice. An in vitro study revealed that Apelin/APJ system suppressed apoptosis in a dose-dependent manner, and increased proliferation of primary mouse osteoblasts. These results demonstrate that Apelin/APJ system is a physiologically important antianabolic factor in vitro [84] . Apelin/APJ system plays a key role in controlling skeletal homeostasis both in vitro and in vivo.
Apelin/APJ system provides gastrointestinal cytoprotection by mediating apoptosis Apelin/APJ system is considered as an important regulatory gut peptide with a potential physiological role in gastrointestinal cytoprotection. Apelin-13 in rat gastrointestinal tract reduces apoptosis, mitosis, and the number of DNA damages. Apelin-13 improves the overall gut health by reducing the cell turnover in the upper gastrointestinal tract epithelium and pancreas [36] . It has been demonstrated that Apelin/ APJ system also reduces the cell turnover in the rat stomach and small intestine. The mechanism is that Apelin-12 inhibits the apoptosis of rat intestinal crypt IEC-6 cells and promotes the apoptosis of enterocyte Caco-2 cells [85] . Additionally, Apelin/APJ system affects the DNA repair process and has cytoprotective properties through low expression of the DNA repair enzyme in intestinal cell lines. These results indicate that Apelin/APJ system signaling is a promising pharmacological target for the cytoprotective properties.
Conclusions and Perspectives
Apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis, nervous system, gastrointestinal system, and skeletal homeostasis, and may be involved in the pathogenesis of hypertension, heart failure, atherosclerosis, PAH, acute renal injury, and other diseases. Apelin-13 protects rat hearts from IR injury by inhibiting endoplasmic reticulum-dependent apoptosis in cardiovascular system. Apelin-13 also shows anti-apoptotic or pro-apoptotic functions in the nervous system and gastrointestinal system. Apelin/ APJ system functions in these diseases, and homologous analogs of Apelin may act as novel drugs [86] . The results from our lab demonstrate that the cardiovascular system is the main target of APJ and Apelin. Apelin-13 is the predominant isoform in cardiac tissue. The peptide agonists designed based on Apelin-13 may be used to treat APJ-related hypertension and other cardiovascular diseases. The function of APJ peptidic agonists and antagonists [87, 88] is similar to that of Apelin. Therefore, we speculate that these APJ agonists and antagonists may be used as novel drug targets for these diseases, and Apelin/APJ system acting on apoptosis may be a promising therapy target for diseases.
More studies are required to explore the new roles of the Apelin/ APJ system and its underlying mechanism in different directions and perspectives. Further exploration of the relationship between Apelin/ APJ system and apoptosis will facilitate the discovery of potential targets for diseases and help to find new and effective drugs to cure diseases and alleviate the sufferings of patients.
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